1
|
Coloma I, Parrón-Ballesteros J, Cortijo M, Cuerva C, Turnay J, Herrero S. Overcoming Resistance of Caco-2 Cells to 5-Fluorouracil through Diruthenium Complex Encapsulation in PMMA Nanoparticles. Inorg Chem 2024; 63:12870-12879. [PMID: 38833385 PMCID: PMC11256753 DOI: 10.1021/acs.inorgchem.4c01323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2024] [Revised: 05/08/2024] [Accepted: 05/23/2024] [Indexed: 06/06/2024]
Abstract
Drug resistance, one of the main drawbacks in cancer chemotherapy, can be tackled by employing a combination of drugs that target different biological processes in the cell, enhancing the therapeutic efficacy. Herein, we report the synthesis and characterization of a new paddlewheel diruthenium complex that includes 5-fluorouracil (5-FU), a commonly used anticancer drug. This drug was functionalized with a carboxylate group to take advantage of the previously demonstrated release capacity of carboxylate ligands from the diruthenium core. The resulting hydrophobic complex, [Ru2Cl(DPhF)3(5-FUA)] (Ru-5-FUA) (DPhF = N,N'-diphenylformamidinate; 5-FUA = 5-fluorouracil-1-acetate) was subsequently entrapped in poly(methyl methacrylate) (PMMA) nanoparticles (PMMA@Ru-5-FUA) via a reprecipitation method to be transported in biological media. The optimized encapsulation procedure yielded particles with an average size of 81.2 nm, a PDI of 0.11, and a zeta potential of 29.2 mV. The cytotoxicity of the particles was tested in vitro using the human colon carcinoma cell line Caco-2. The IC50 (half maximal inhibitory concentration) of PMMA@Ru-5-FUA (6.08 μM) was just slightly lower than that found for the drug 5-FU (7.64 μM). Most importantly, while cells seemed to have developed drug resistance against 5-FU, PMMA@Ru-5-FUA showed an almost complete lethality at ∼30 μM. Conversely, an analogous diruthenium complex devoid of the 5-FU moiety, [Ru2Cl(DPhF)3(O2CCH3)] (PMMA@RuA), displayed a reduced cytotoxicity at equivalent concentrations. These findings highlight the effect of combining the anticancer properties of 5-FU with those of diruthenium species. This suggests that the distinct modes of action of the two chemical species are crucial for overcoming drug resistance.
Collapse
Affiliation(s)
- Isabel Coloma
- MatMoPol
Research Group, Inorganic Chemistry Department, Faculty of Chemical
Sciences, Complutense University of Madrid, E-28040 Madrid, Spain
| | - Jorge Parrón-Ballesteros
- Department
of Biochemistry and Molecular Biology, Faculty of Chemical Sciences, Complutense University of Madrid, E-28040 Madrid, Spain
| | - Miguel Cortijo
- MatMoPol
Research Group, Inorganic Chemistry Department, Faculty of Chemical
Sciences, Complutense University of Madrid, E-28040 Madrid, Spain
| | - Cristián Cuerva
- MatMoPol
Research Group, Inorganic Chemistry Department, Faculty of Chemical
Sciences, Complutense University of Madrid, E-28040 Madrid, Spain
| | - Javier Turnay
- Department
of Biochemistry and Molecular Biology, Faculty of Chemical Sciences, Complutense University of Madrid, E-28040 Madrid, Spain
| | - Santiago Herrero
- MatMoPol
Research Group, Inorganic Chemistry Department, Faculty of Chemical
Sciences, Complutense University of Madrid, E-28040 Madrid, Spain
| |
Collapse
|
2
|
Ji Q, Zhu H, Qin Y, Zhang R, Wang L, Zhang E, Zhou X, Meng R. GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs. Front Pharmacol 2024; 15:1329636. [PMID: 38323081 PMCID: PMC10844528 DOI: 10.3389/fphar.2024.1329636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 01/08/2024] [Indexed: 02/08/2024] Open
Abstract
Albumin is derived from human or animal blood, and its ability to bind to a large number of endogenous or exogenous biomolecules makes it an ideal drug carrier. As a result, albumin-based drug delivery systems are increasingly being studied. With these in mind, detailed studies of the transport mechanism of albumin-based drug carriers are particularly important. As albumin receptors, glycoprotein 60 (GP60) and secreted protein acidic and rich in cysteine (SPARC) play a crucial role in the delivery of albumin-based drug carriers. GP60 is expressed on vascular endothelial cells and enables albumin to cross the vascular endothelial cell layer, and SPARC is overexpressed in many types of tumor cells, while it is minimally expressed in normal tissue cells. Thus, this review supplements existing articles by detailing the research history and specific biological functions of GP60 or SPARC and research advances in the delivery of antitumor drugs using albumin as a carrier. Meanwhile, the deficiencies and future perspectives in the study of the interaction of albumin with GP60 and SPARC are also pointed out.
Collapse
Affiliation(s)
- Qingzhi Ji
- School of Pharmacy, Yancheng Teachers University, Yancheng, China
| | - Huimin Zhu
- Sheyang County Comprehensive Inspection and Testing Center, Yancheng, China
| | - Yuting Qin
- School of Pharmacy, Yancheng Teachers University, Yancheng, China
| | - Ruiya Zhang
- Department of Immunology, Medical School, Nantong University, Nantong, China
| | - Lei Wang
- Department of Immunology, Medical School, Nantong University, Nantong, China
| | - Erhao Zhang
- Department of Immunology, Medical School, Nantong University, Nantong, China
| | - Xiaorong Zhou
- Department of Immunology, Medical School, Nantong University, Nantong, China
| | - Run Meng
- Department of Immunology, Medical School, Nantong University, Nantong, China
| |
Collapse
|
3
|
Tumor Cell Capture Using Platelet-Based and Platelet-Mimicking Modified Human Serum Albumin Submicron Particles. Int J Mol Sci 2022; 23:ijms232214277. [PMID: 36430755 PMCID: PMC9694380 DOI: 10.3390/ijms232214277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 11/09/2022] [Accepted: 11/14/2022] [Indexed: 11/19/2022] Open
Abstract
The co-localization of platelets and tumor cells in hematogenous metastases has long been recognized. Interactions between platelets and circulating tumor cells (CTCs) contribute to tumor cell survival and migration via the vasculature into other tissues. Taking advantage of the interactions between platelets and tumor cells, two schemes, direct and indirect, were proposed to target the modified human serum albumin submicron particles (HSA-MPs) towards tumor cells. HSA-MPs were constructed by the Co-precipitation-Crosslinking-Dissolution (CCD) method. The anti-CD41 antibody or CD62P protein was linked to the HSA-MPs separately via 1-ethyl-3-(-3-dimethyl aminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) EDC/NHS chemistry. The size of modified HSA-MPs was measured at approximately 1 µm, and the zeta potential was around -24 mV. Anti-CD41-HSA-MPs adhered to platelets as shown by flowcytometry and confocal laser scanning microscopy. In vitro, we confirmed the adhesion of platelets to tumor lung carcinoma cells A549 under shearing conditions. Higher cellular uptake of anti-CD41-HSA-MPs in A549 cells was found in the presence of activated platelets, suggesting that activated platelets can mediate the uptake of these particles. RNA-seq data in the Cancer Cell Lineage Encyclopedia (CCLE) and The Cancer Genome Atlas (TCGA) database showed the expression of CD62P ligands in different types of cancers. Compared to the non-targeted system, CD62P-HSA-MPs were found to have higher cellular uptake in A549 cells. Our results suggest that the platelet-based and platelet-mimicking modified HSA-MPs could be promising options for tracking metastatic cancer.
Collapse
|
4
|
Chaiwaree S, Prapan A, Suwannasom N, Laporte T, Neumann T, Pruß A, Georgieva R, Bäumler H. Doxorubicin-Loaded Human Serum Albumin Submicron Particles: Preparation, Characterization and In Vitro Cellular Uptake. Pharmaceutics 2020; 12:pharmaceutics12030224. [PMID: 32131545 PMCID: PMC7150780 DOI: 10.3390/pharmaceutics12030224] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 02/28/2020] [Accepted: 02/28/2020] [Indexed: 12/16/2022] Open
Abstract
Doxorubicin (DOX) is an effective anthracycline antibiotic drug which is commonly used in a broad range cancer therapy. However, due to dose depending side effects and toxicity to non-cancerous tissues, its clinical applications are restricted. To overcome these limitations, human serum albumin (HSA) has been investigated as a biocompatible drug delivery vehicle. In this study, human serum albumin submicron particles (HSA-MPs) were fabricated by using the Co-precipitation–Crosslinking–Dissolution technique (CCD technique) and DOX was loaded into the protein particles by absorption. DOX-HSA-MPs showed uniform peanut-like shape, submicron size and negative zeta-potential (−13 mV). The DOX entrapment efficiency was 25% of the initial amount. The in vitro release in phosphate buffered saline pH 7.4 was less than 1% within 5 h. In contrast, up to 40% of the entrapped DOX was released in presence of a protein digesting enzyme mixture (Pronase®) within the same time. In addition, in vitro cytotoxicity and cellular uptake of DOX-HSA-MPs were evaluated using the lung carcinoma cell line A549. The results demonstrated that DOX-HSA-MPs reduced the cell metabolic activities after 72 h. Interestingly, DOX-HSA-MPs were taken up by A549 cells up to 98% and localized in the cell lysosomal compartment. This study suggests that DOX-HSA-MPs which was fabricated by CCD technique is seen as a promising biopolymer particle as well as a viable alternative for drug delivery application to use for cancer therapy.
Collapse
Affiliation(s)
- Saranya Chaiwaree
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; (S.C.); (A.P.); (N.S.); (T.L.); (A.P.); (R.G.)
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Payap University, Chiang Mai 50000, Thailand
| | - Ausanai Prapan
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; (S.C.); (A.P.); (N.S.); (T.L.); (A.P.); (R.G.)
- Department of Radiological Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand
| | - Nittiya Suwannasom
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; (S.C.); (A.P.); (N.S.); (T.L.); (A.P.); (R.G.)
- Division of Biochemistry, School of Medical Sciences, University of Phayao, Phayao 56000, Thailand
| | - Tomás Laporte
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; (S.C.); (A.P.); (N.S.); (T.L.); (A.P.); (R.G.)
- Instituto de Nanosistemas, Universidad Nacional de San Martín, San Martín, Pcia de Buenos Aires 1021, Argentina
| | - Tanja Neumann
- JPK BioAFM Business, Nano Surfaces Division, Bruker Nano GmbH, 12489 Berlin, Germany;
| | - Axel Pruß
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; (S.C.); (A.P.); (N.S.); (T.L.); (A.P.); (R.G.)
| | - Radostina Georgieva
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; (S.C.); (A.P.); (N.S.); (T.L.); (A.P.); (R.G.)
- Department of Medical Physics, Biophysics and Radiology, Medical Faculty, Trakia University, 6000 Stara Zagora, Bulgaria
| | - Hans Bäumler
- Institute of Transfusion Medicine, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; (S.C.); (A.P.); (N.S.); (T.L.); (A.P.); (R.G.)
- Correspondence: ; Tel.: +49-30-450525131
| |
Collapse
|
5
|
Jin Z, Chi M, He Q, Pan Y, Sun C. Perfluoroalkane sulfonyl fluorides non-covalently bind to human serum albumin at Sudlow’s sites. Toxicol Lett 2019; 301:17-23. [DOI: 10.1016/j.toxlet.2018.11.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 10/10/2018] [Accepted: 11/04/2018] [Indexed: 01/29/2023]
|
6
|
In vitro and in vivo cytotoxic activity and human serum albumin interaction for a methoxy-styryl-thiosemicarbazone. Invest New Drugs 2019; 37:994-1005. [PMID: 30661149 DOI: 10.1007/s10637-018-00722-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2018] [Accepted: 12/26/2018] [Indexed: 12/15/2022]
Abstract
Thiosemicarbazone is a class of compounds with potential applications in medicine, presenting high capacity to inhibit the growth of cancer cells as well as low toxicity. Because of high interest in anticancer studies involving thiosemicarbazones as new chemotherapeutic agents, a synthetic thiosemicarbazone derivative, 4-N-(2'-methoxy-styryl)-thiosemicarbazone (MTSC) was evaluated in vivo against Ehrlich carcinoma in an animal model. In vivo results demonstrated that MTSC treatment induced the survival of mice and altered significantly the body weight of the surviving mice 12 days after tumor inoculation. Treatment with 30 mg/kg of MTSC exhibited effective cytotoxic activity with T/C values of 150.49% (1 dose) and 278% (2 doses). Its interaction with human serum albumin (HSA), which plays a crucial role in the biodistribution of a wide variety of ligands, was investigated by multiple spectroscopic techniques at 296 K, 303 K, and 310 K, as well as by theoretical calculations. The interaction between HSA and MTSC occurs via ground-state association in the subdomain IIA (Sudlow's site I). The binding is moderate (Ka ≈ 104 M-1), spontaneous, entropically, and enthalpically driven. Molecular docking results suggested hydrogen bonding and hydrophobic interactions as the main binding forces. Overall, the interaction HSA:MTSC could provide therapeutic benefits, improving its cytotoxic efficacy and tolerability.
Collapse
|